
Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

VectivBio taken over in $1bn acquisition
VectivBio Holding AG has entered into a acquisition agreement with Ironwood Pharmaceuticals Inc. Ironwood will launch a tender offer to buy...

eXmoor Pharma Ltd raises US$35m
The financing of eXmoor Pharma Ltd. was led by new investor Kineticos Ventures and existing investor MVM Partners to help launching...

Ariceum Therapeutics extends Series A to €47.75m
The Series A financing was co-led by new investors Andera Partners and Earlybird Venture Capital. Existing investor Pureos Bioventures doubled its...

Forbion raises €1.35bn across two funds
Both funds, the early stage Forbion Ventures Fund VI (€750m) and the Forbion Growth Opportunities Fund II (€600m), which will invest up to €70m in up...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Glioma drug combo turns tumours hot
Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...